Assistant Professor, Department of Biochemistry, Yong Loo Lin School of Medicine, NUS.
Adjunct Scientist, Bioinformatics Institute, A*STAR.
Adjunct Scientist, Singapore Eye Research Institute.
Faculty, NUS Graduate School of Integrative Sciences and Engineering.
Affiliate, National University Cancer Institute of Singapore.
Teaching Faculty, Division of Graduate Medical Studies, Yong Loo Lin School of Medicine, NUS.
|Degree and Institution||Year(s)|
|National University of Singapore||1990 - 1994|
|Institute of Molecular and Cell Biology, A*STAR||1994 - 1999|
|Position and Institute||Year(s)|
|Dana-Farber Cancer Institute, Boston, USA||1999 – 2000|
|National Cancer Centre of Singapore||2001 – 2004|
|Oncology Research Institute/Cancer Science Institute||2005 – 2011|
Lim Yoon Pin is one of pioneers to develop and apply cutting-edge liquid chromatography/mass spectrometry-based phosphoproteomic technologies to oncogenic signalling and cancer research. He has published more than 50 peer-reviewed articles in the area of signal transduction, cancer research and biomarker discovery. He has filed more than 30 patents, granted 11 patents from USA, China and Singapore while the rest are pending award. Four of his inventions are licensed to an MNC and SME. Through phosphoproteomics, he discovered WBP2, WW domain binding protein 2, to be a novel breast cancer associated protein and a substrate of the well-known EGF Receptor Tyrosine Kinase oncogene. Subsequently, he demonstrated WBP2 to be an oncogene that works by activating multiple oncogenic pathways such as Estrogen Receptor and Wnt signalling. His lab is expanding WBP2 research to other epithelial cancers and signalling pathways like Hippo signalling. Along with Hong Wanjin, Lim Yoon Pin is considered to be the first to prove WBP2 as a breast cancer oncogene. His lab’s efforts in WBP2 research and its impact on the Wnt and Hippo signalling are recognised internationally. He works with collaborators from Australia, Germany, USA and Singapore.
Lim Yoon Pin’s laboratory focuses on:
- Signal Transduction of RTKs, Wnt and Hippo pathways
- Epithelial Cancer Research
- Biomarker and Drug target Discovery
- Proteomics and Phosphoproteomics Technologies
Selected Publications (Out of 53)
- Kang SA, Guan JS, Tan HJ, Thike AA, Eichhorn PJA, Arribas J, Tan PH, Putti TC, Gudi M, Sohn J, Lim SH, Lee SC and Lim YP. Elevated WBP2 expression in HER2-positive breast cancers correlates with sensitivity to trastuzumab-based neo-adjuvant therapy:A Retrospective and Multicentric Study. 2018 Clin. Cancer Res. In press (2017 IF: 10.2)
- Li Z, Lim SK, Liang X, Lim YP. The transcriptional coactivator WBP2 primes triple-negative breast cancer cells for responses to Wnt signaling via the JNK/Jun kinase pathway. 2018. J. Biol. Chem. Manuscript accepted. (5-year IF: 4.2)
- Ramos A, Miow QH, Liang X, Lin QS, Putti TC and Lim YP. Phosphorylation of E-box binding USF-1 by PI3K/AKT enhances its transcriptional activation of the WBP2 oncogene in breast cancer cells. 2018 FASEB J Manuscript accepted (5-year IF: 5.4)
- Lee WH, Choong LY, Tan HJ, Mon NN, Chong PK, Liew CS, Putti TC, Lu S, Harteneck C and Lim YP. TRPV4 plays a role in breast cancer cell migration via Ca2+ dependent activation of AKT and down-regulation of E-cadherin cell cortex protein. Oncogenesis 2017 May 22; 6(5):e338 (5-year IF: 4.6)
- Lim SK, Lu S, Kang SA, Tan HJ, Li Z, Wee ZNA, Guan JS, Chichili VPR, Sivaraman J, Putti TC, Thike AA, Tan PH, Sudol M, Virshup DM, Chan SW, Hong WJ and Lim YP. Wnt Signaling Promotes Breast Cancer By Blocking ITCH-Mediated Degradation of YAP/TAZ transcription Co-activator WBP2. 2016 Cancer Res. 76(21):6278-6289 (5-year IF: 9.2)
- Lee WH, Choong LY, Mon NN, Lu SY, Liew CS, Tan KY, Lin QS, Pang MF, Pan M, Pang B, Krishna SRV, Druker BJ, OW GS, Kuznetsov V, Tan TZ, Goh LK, Thiery JP, Tan PBO, Lim CT, Harteneck C and Lim YP. TRPV4 Regulates Breast Cancer Cell Extravasation, Stiffness and Actin Cortex. 2016 Sci. Rep. 6:27903 (5-year IF: 5.5)
- Hou A, Law KP, Tan MQ, Lim YP, Tong L. In vitro Secretomics study of Pterygium-derived Fibroblasts by iTRAQ-based Quantitative Proteomics Strategy. Exp Eye Res 2016 153:14-22 (5-year IF: 3.0)
- Toh CXD, EL Farran CA, Chong ZS, Wang HF, Tan YS, Maury JJ, Guo HC, Ma D, Goh GYL, Chang YT, Collins JJ, Daley GQ, Li H, Lim YP, Bard FA, Loh YH. Global Regulators Controlling Human Somatic Cell Reprogramming. 2016 Cell Reports. 15(12):2597-2607 (5-year IF: 8.1)
- Man X, Megraw TL, Lim YP. Cep68 can be regulated by by Nek2 and SCF complex. 2015 Eur. J. Cell. Biol. 94:162–172 (5-year IF: 3.7)
- Hay SH, Shin EM, Lee MH, Goh JN, Ong HT, Arkasubhra G, Wong M, Ong CW, W Sun, Kong X, Salto-Tellez M, Putti TC, Lim CT, Lobie PE, Lim YP, YAP CT, Sethi Gautam, Lee M, Tan P, Miller LD, Hui K, Zhu T, Miyamoto S, Kumar AP, Tergaonkar V. Dead-box DP103, an essential regulator of NEMO SUMOylation and NF-kB activation, defines the metastatic potential of human breast cancer. 2014 J. Clin. Invest. 124(9):3807-24 (5-year IF: 14.7)
- Wee ZN, Li Z, Lee PL, Lee ST, Lim YP, Yu Q. EZH2-Mediated Inactivation of IFN-γ-JAK-STAT1 Signaling Is an Effective Therapeutic Target in MYC-Driven Prostate Cancer. 2014 Cell Reports 8, 1–13, (IF: 7.2)
- Manjeet M, Soah YC, Ng C, Yusoff P, Rebecca A. Jackson, Yew JX, Yim D, Iyu A, Koh XW, Risgar NF, Li D, Saravanan S, Lim YP, Guy GR and Sivaraman J. A novel dimer consisting of a pair of RING domains and Zinc finger domains constitutes the phosphotyrosine-binding domain of the Hakai Ubiquitin E3 ligase protein that targets E-Cadherin, Cortactin and other Src substrates. 2012 EMBO J 31(5):1308-19 (5 year IF: 9.4)
- Lim SK, Orhant-Prioux M, Toy W, Tan KY and Lim YP. Tyrosine Phosphorylation of Transcription Coactivator WW-Domain Binding Protein 2 Regulates Estrogen Receptor α Function in Breast Cancer via Wnt Crosstalk. 2011 FASEB J. Sep;25(9):3004-18. Epub 2011 Jun 3 (5-year IF: 7.2)
- Zhou J, Pan M, Xie Z, Loh SL, Bi C, Tai YC, Lilly M, Lim YP, Han JH, Glaser KB, Albert DH, Davidsen SK, Chen CS. Synergistic anti-leukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway. 2008 Leukemia 22, 138–146 (5-year IF: 6.89)
- Chen Y, Choong LY, Lin QS, Philps, R, Wong CH, Ang BK, Loh MCS, Hew CL, Shah, N, Druker BJ, Chong PK and Lim YP. Differential expression of novel tyrosine kinase substrates during breast cancer development. 2007 Mol. Cell. Proteomics 6(12):2072-87 (5-year IF: 9.39)
- Choong LY, Lim S, Loh MCS, Man X, Chen Y, Toy W, Tan YL, Pang M, Chen CS, Poonepalli A, Hande PM, Tan PH, Salto-Tellez M, Wong CY, Shah N, Druker BJ and Lim YP. Progressive loss of EGFR in a sub-population of breast cancers – implications in target-directed therapeutics. 2007 Mol. Cancer Ther. 6(11):2828–42 (5-year IF: 5.43)
- Lim YP. Mining the tumor phosphoproteome for molecular cancer markers. 2005 Clin Cancer Res. 11: 3163-3169. (5-year IF: 6.65)
- Lim YP, Wong CY, Ooi LL, Druker BJ and Epstein RJ. Selective tyrosine hyperphosphorylation of cytoskeletal and stress proteins in primary human breast cancers: implications for adjuvant use of kinase-inhibitory drugs. 2004 Clin. Cancer Res. 10:3980-3987. (5-year IF: 6.65)
- Lim YP, Diong LS, Qi R, Druker, BJ and Epstein, RJ. Phosphoproteomic fingerprinting of growth factor signaling and anticancer drug action in human tumor cells. 2003 Mol. Cancer Ther. 2(12): 1369-1377. (5-year IF: 5.43)
- Lim YP, Low BC, Lim J, Wong ES, Guy GR. Association of atypical protein kinase C isotypes with the docker protein FRS2 in fibroblast growth factor signaling. 1999 J. Biol. Chem. Jul 2;274(27):19025-34. (5-year IF: 5.57)
- B C Low, Lim YP, Lim J, Wong ES, Guy GR. Tyrosine phosphorylation of the Bcl-2-associated protein BNIP-2 by fibroblast growth factor receptor-1 prevents its binding to Cdc42GAP and Cdc42. 1999 J. Biol. Chem. Nov 12;274(46):33123-30. (5-year IF: 5.57)
- Lim YP, Low BC, Ong SH, Guy GR. Growth factors stimulate tyrosine dephosphorylation of p75 and its dissociation from the SH2 domain of Grb2. 1997 J. Biol. Chem. Nov 21;272(47):29892-8. (5-year IF: 5.57)